Omeros Corporation (OMER)

NASDAQ: OMER · IEX Real-Time Price · USD
7.48
+0.07 (0.94%)
Jun 5, 2023, 12:16 PM EDT - Market open
0.94%
Market Cap 471.84M
Revenue (ttm) n/a
Net Income (ttm) 46.73M
Shares Out 62.83M
EPS (ttm) 0.75
PE Ratio 9.88
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 184,057
Open 7.45
Previous Close 7.41
Day's Range 7.38 - 7.80
52-Week Range 1.74 - 7.80
Beta 1.10
Analysts Hold
Price Target 3.00 (-59.89%)
Earnings Date May 9, 2023

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2009
Employees 196
Stock Exchange NASDAQ
Ticker Symbol OMER
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for OMER stock is "Hold." The 12-month stock price forecast is $3.0, which is a decrease of -59.89% from the latest price.

Price Target
$3.0
(-59.89% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company's lead MASP-3 ...

4 days ago - Business Wire

Omeros Corporation Reports First Quarter 2023 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

3 weeks ago - Business Wire

Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 202...

1 month ago - Business Wire
}

Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company's lead ...

1 month ago - Business Wire

Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health...

2 months ago - Business Wire

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

2 months ago - Business Wire

Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank. Omeros pr...

3 months ago - Business Wire

Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Mo...

3 months ago - Business Wire
}

Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset Purchase A...

4 months ago - Business Wire

Omeros Corporation Reports Third Quarter 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

7 months ago - Business Wire

Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has reached a decision on the company's fo...

7 months ago - Business Wire

Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, Nove...

7 months ago - Business Wire

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two presentations pertaining to Omeros' investigational complement inhibitors will be featured at the upcoming 64th Ame...

7 months ago - Business Wire
}

Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Omeros has sold to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, an intere...

8 months ago - Business Wire

Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Analysi...

9 months ago - Business Wire

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19

SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)--Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, and Omeros Corporation (NASDAQ: OMER), developer of the investigational agent ...

9 months ago - Business Wire

Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the United States Food and Drug Administration (FDA) provided an interim response to the company's formal dispute resol...

10 months ago - Business Wire

Omeros Corporation Reports Second Quarter 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

10 months ago - Business Wire

Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, ...

10 months ago - Business Wire

FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal...

11 months ago - Business Wire

Omeros Announces Webcast Details for Annual Meeting of Shareholders

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually, on Friday, J...

1 year ago - Business Wire

Omeros Corporation Reports First Quarter 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

1 year ago - Business Wire

Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022, on Tuesday, May 10, 20...

1 year ago - Business Wire

Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the online publication of a manuscript detailing the results of its pivotal study assessing efficacy and safety of narsoplim...

1 year ago - Business Wire

Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...

1 year ago - Business Wire